top of page
The Sage Group is at JPM/BIO Partnering in San Francisco from 13-16 January, 2025! Please click here to setup a meeting!
See Latest News!
30 YEARS OF GLOBAL TRANSACTIONS FOR BIOSCIENCE COMPANIES
The Sage Group
About
Track Record
Locations
Added Value
Sage Clients
Testimonials
Services
M & A
Licensing
Sage China
Sage Japan
Sage India
Team
News
Downloads
Contact
More
Use tab to navigate through the menu items.
Sage Group News
The Sage Group: 30 Years of Successful Bioscience Transactions
London and New York, September 1 2024 Â - The Sage Group ( www.sagehealthcare.com ), a leading global advisor in the bioscience sector,...
Coagulant’s CT-001 - An Opportunity To License A Novel Factor VIIa with Orphan Drug Designation for the Treatment of Severe Postpartum Hemorrhage (sPPH)
Our client, Coagulant Therapeutics Corporation (CTC), is developing a novel, patented (4 families due to expire 2041-2043 period)...
Partnering/Licensing Opportunity for Tecarfarin, a Phase 3-Ready Oral Anticoagulant for Patients with Certain Orphan Diseases
Cadrenal Therapeutics ( www.cadrenal.com ; NASDAQ: CVKD) is a public U.S. company focused on advancing the development and...
bottom of page
